[Comment] Accelerating neoadjuvant chemotherapy for muscle-invasive bladder cancer

The efficacy of neoadjuvant chemotherapy before radical cystectomy for individuals with muscle-invasive bladder cancer has been evidenced since the 1990s. Although the clinical benefit of cisplatin-containing regimens is indisputable, establishing the optimal scheme has been a challenge, requiring the evaluation of efficacy, toxicity, and effect on surgical resection. In current clinical practice, the chemotherapeutic regimens most commonly used have not been tested in phase 3 trials in the neoadjuvant setting.